纳武利尤单抗-AVD对比维布妥昔单抗-AVD治疗青少年晚期经典型霍奇金淋巴瘤的三年随访
S1826随机III期试验的青少年亚组分析,比较N-AVD与BV-AVD在新诊断晚期经典型霍奇金淋巴瘤中的疗效。240例12-17岁患者中,N-AVD组3年无进展生存率显著高于BV-AVD组(93% vs 82%;HR 0.37)。N-AVD组甲状腺功能障碍发生率7%,BV-AVD组≥2级感觉神经病变更常见(14% vs 7%)。
要点
- N-AVD方案3年PFS显著优于BV-AVD(93% vs 82%;HR 0.37)。
- N-AVD组严重免疫相关不良事件少见,甲状腺功能障碍发生率7%。
- BV-AVD组≥2级感觉神经病变更常见(14% vs 7%)。
核心结论
- N-AVD在青少年晚期经典型霍奇金淋巴瘤中显示高3年PFS,且放疗使用极少。
研究设计与样本
- S1826随机III期试验的青少年亚组分析,纳入240例12-17岁新诊断晚期(III/IV期)经典型霍奇金淋巴瘤患者。
主要发现
- N-AVD组3年PFS为93%(95% CI 87-96),BV-AVD组为82%(95% CI 73-88),风险比0.37(95% CI 0.17-0.80)。
- N-AVD组1例、BV-AVD组2例接受方案规定的残留部位放疗。
- 两组发热性中性粒细胞减少和脓毒症发生率均低。
- N-AVD组甲状腺功能障碍发生率为7%。
- BV-AVD组≥2级感觉神经病变更常见(14% vs 7%)。
临床怎么用
- 对于青少年晚期经典型霍奇金淋巴瘤,N-AVD方案可提供高3年PFS且放疗使用少。
- 需关注N-AVD相关甲状腺功能障碍及BV-AVD相关感觉神经病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.
引用
- Castellino SM, Li H, Herrera AF, et al. Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826. J Clin Oncol. 2026. PMID: 41512237. doi:10.1200/JCO-25-00203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。